Oral ribavirin for paramyxovirus infection after alemtuzumab‐containing reduced‐intensity conditioning HCT regimen

Dreyzin, Alexandra; Michaels, Marian G.; Lugt, Mark T. Vander; Szabolcs, Paul

doi:10.1111/petr.13358

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug has shown favorable results in some small case series and case reports. The benefit of using oral ribavirin has been described in children with HSCT and lung transplant recipients, and both RSV and PIV infections were included in these series [ 3 , 23 , 24 ]. However, it is difficult to draw a conclusion about the benefit of oral ribavirin, as these reports did not have a comparator treatment arm.…”

Section: Discussionmentioning

confidence: 99%

Hemophilus influenzae and Parainfluenza Virus Pneumonia in a Patient with AIDS

Nagarakanti

Bishburg

2020

Am J Case Rep

View full text Add to dashboard Cite

Patient: Male, 64-year-old Final Diagnosis: Hemophilus influenzae and parainfluenza virus pneumonia in a patient with AIDS Symptoms: Shortness of breath Medication:— Clinical Procedure: Bronchoalveolar lavage Specialty: Infectious Diseases Objective: Rare disease Background: Parainfluenza viruses (PIV) are known to cause mild respiratory tract infections in immunocompetent patients but can cause severe infections in immune-compromised patients such as transplant recipients and children with HIV. PIV infection in HIV-infected adults has rarely been reported. We report a case of PIV pneumonia in an adult with AIDS who was successfully treated with oral ribavirin. Case Report: A 64-year-old man with history of acquired immune deficiency syndrome (AIDS) was admitted to the hospital with shortness of breath that began 3 days before. He was in respiratory distress and required mechanical ventilation on arrival. A bronchoalveolar lavage (BAL) culture was positive for Hemophilus influenzae and a respiratory viral panel was positive for Parainfluenza virus. The patient was initially started on Cefepime and Trimethoprim- Sulfamethoxazole and later changed to Ceftriaxone based on culture results. As the patient’s condition did not improve after 48 h, oral ribavirin was added to treat PIV. The patient subsequently improved and was extubated after 72 h. Conclusions: Oral ribavirin can have a beneficial effect in AIDS patients who have PIV-associated pneumonia. Further investigation of the benefit of oral ribavirin in similar cases is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%